News & Updates
Filter by Specialty:
SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout
Use of an SGLT-2 inhibitor, compared with a GLP-1 receptor agonist or a DPP-4 inhibitor, helps to prevent nephrolithiasis from recurring in patients with type 2 diabetes (T2D) and pre-existing nephrolithiasis or gout, as shown in target trial emulation studies.
SGLT-2 inhibitors stop kidney stone recurrence in T2D patients with nephrolithiasis, gout
13 Nov 2024
Prompt DOAC therapy after stroke safe for AF patients
Initiating direct oral anticoagulants (DOACs) within 4 days after an ischaemic stroke in patients with atrial fibrillation (AF) is safe and yields similar outcomes as delayed initiation, as shown in the phase 4 OPTIMAS trial.
Prompt DOAC therapy after stroke safe for AF patients
11 Nov 2024
Elagolix on par with dienogest for endometriosis-related pain
In the treatment of pain due to endometriosis, use of elagolix 150-mg tablets demonstrates comparable efficacy to dienogest 2-mg tablets, as assessed via numeric rating scale (NRS) score from baseline to day 85 and 169, according to a study presented at RCOG 2024. Additionally, both drugs are well tolerated.
Elagolix on par with dienogest for endometriosis-related pain
11 Nov 2024
Oral misoprostol solution measures up to tablet formulation for labour induction
The off-label oral solution of misoprostol proves noninferior to the licensed oral tablet for induction of labour, with no significant difference in the occurrence of vaginal delivery within 24 hours, according to a study.